tirzepatide a peptide TIRZ GLP-2 10mg & 30mg | Premium Research Peptide Buy the Tirzepatide | Research

3 After propensity-score matching for age, BMI, breast density, race, ethnicity, and diabetes history (n=30,528), breast cancer occurred in 1.62% (247/15,264) of GLP-1 users over the study period of 3.5 years, compared with 2.31% (353/15,264) of matched non-users

For broader nutrition context with GLP1 therapies, see Diet and Weight Loss for practical meal-planning guardrails during treatment

Compared to other peptides and therapiessuch as direct growth hormone injections or other secretagogues like Ipamorelin or CJC-1295Sermorelin is generally associated with a more favorable safety profile

Tirzepatide has completed the SURMOUNT Phase 3 programme and is in routine UK clinical use as Mounjaro